Trial Profile

A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD19 Chimeric Antigen Receptor T cell therapy Takara Bio (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Mesna (Primary)
Indications Lymphoid leukaemia
Focus Adverse reactions

16 Jul 2025 Planned End Date changed from 1 Jun 2027 to 1 Jul 2028.
16 Jul 2025 Planned primary completion date changed from 1 Jun 2026 to 1 Jul 2027.
31 Jan 2024 Planned End Date changed from 1 Jan 2026 to 1 Jun 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com